Skin infections among Indigenous Australians in an urban setting in Far North QueenslandVALERY, P. C; WENITONG, M; CLEMENTS, V et al.Epidemiology and infection. 2008, Vol 136, Num 8, pp 1103-1108, issn 0950-2688, 6 p.Article

Saving Costs on School BuildingSIMPSON, B; CLEMENTS, V; WOODFALL, K et al.Educational research (Windsor). 1981, Vol 23, Num 3, pp 214-221, issn 0013-1881Article

Rejection of mouse sarcoma cells after transfection of MHC class II genesOSTRAND-ROSENBERG, S; THAKUR, A; CLEMENTS, V et al.The Journal of immunology (1950). 1990, Vol 144, Num 10, pp 4068-4071, issn 0022-1767Article

Resistance to 402AX teratocarcinoma involves immunity to minor histocompatibility antigensOSTRAND-ROSENBERG, S; CLEMENTS, V.Immunogenetics (New York, NY). 1987, Vol 26, Num 1-2, pp 1-5, issn 0093-7711Article

402AX Teratocarcinoma MHC class I antigen expression is regulated in vivo by Lyt 1, Lyt 2, and L3T4 expressing splenic T cellsOSTRAND-ROSENBERG, S; CLEMENTS, V; MARR, L et al.Cellular immunology (Print). 1986, Vol 98, Num 2, pp 257-265, issn 0008-8749Article

GeneticsDOVE, W. F; BESNARD, C; SCHWARTZMAN, M et al.Cell differentiation. 1984, Vol 15, Num 2-4, pp 205-253, issn 0045-6039Conference Paper

Design conflicts in meeting EMC and safety requirementsCLEMENTS, V. C.IEE conference publication. 1999, pp 190-193, issn 0537-9989, isbn 0-85296-716-0Conference Paper

Class II-transfected tumor cells directly present endogenous antigen to CD4⁺ T cells in vitro and are APCs for tumor-encoded antigens in vivo : T cell response to tumorsARMSTRONG, T. D; CLEMENTS, V. K; OSTRAND-ROSENBERG, S et al.Journal of immunotherapy with emphasis on tumor immunology. 1998, Vol 21, Num 3, pp 218-224, issn 1067-5582Conference Paper

β₂M-/- knockout mice contain low levels of CD8⁺ cytotoxic T lymphocyte that mediate specific tumor rejectionLAMOUSE-SMITH, E; CLEMENTS, V. K; OSTRAND-ROSENBERG, S et al.The Journal of immunology (1950). 1993, Vol 151, Num 11, pp 6283-6290, issn 0022-1767Article

Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II moleculeOSTRAND-ROSENBERG, S; ROBY, C. A; CLEMENTS, V. K et al.The Journal of immunology (1950). 1991, Vol 147, Num 7, pp 2419-2422, issn 0022-1767Article

Transfection of major histocompatibility complex class I and class I genes causes tumour rejectionOSTRAND-ROSENBERG, S; CLEMENTS, V. K; THAKUR, A et al.Journal of immunogenetics. 1989, Vol 16, Num 4-5, pp 343-349, issn 0305-1811Article

Invariant chain alters the malignat phenotype of MHC class II⁺ tumor cellsCLEMENTS, V. K; SIVASUBRAMANIAN BASKAR; ARMSTRONG, T. D et al.The Journal of immunology (1950). 1992, Vol 149, Num 7, pp 2391-2396, issn 0022-1767Article

Immunotherapy with vaccines combining MHC class II/CD80⁺ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon γPULASKI, B. A; CLEMENTS, V. K; PIPELING, M. R et al.Cancer immunology and immunotherapy. 2000, Vol 49, Num 1, pp 34-45, issn 0340-7004Article

Tumor-specific immunity can be enhanced by transfection of tumor cells with syngeneic MHC-class-II genes or allogeneic MHC-class-I genesOSTRAND-ROSENBERG, S; ROBY, C; CLEMENTS, V. K et al.International journal of cancer. 1991, pp 61-68, issn 0020-7136, SUP6Article

Transfection and expression of syngeneic H-2 genes does not reduce malignancy of H-2 negative teratocarcinoma cells in the autologous hostOSTRAND-ROSENBERG, S; COLE, G. A; NISHIMURA, M. I et al.Cellular immunology (Print). 1990, Vol 128, Num 1, pp 152-164, issn 0008-8749, 13 p.Article

Cell-based vaccines for the stimulation of immunity to metastatic cancersOSTRAND-ROSENBERG, S; PULASKI, B. A; CLEMENTS, V. K et al.Immunological reviews. 1999, Vol 170, pp 101-114, issn 0105-2896Article

Embryonal carcinoma cells express Qa and Tla class I genes of the major histocompatibility complexOSTRAND-ROSENBERG, S; NICKERSON, D. A; CLEMENTS, V. K et al.Proceedings of the National Academy of Sciences of the United States of America. 1989, Vol 86, Num 13, pp 5084-5088, issn 0027-8424Article

Allogeneic H-2 antigen expression is insufficient for tumor rejectionCOLE, G. A; COLE, G. A; COLE, G. A; COLE, G. A; CLEMENTS, V. K et al.Proceedings of the National Academy of Sciences of the United States of America. 1987, Vol 84, Num 23, pp 8613-8617, issn 0027-8424Article